Arzerra: new leukaemia antibody

GlaxoSmithKline has launched a new biological treatment for chronic lymphocytic leukaemia (CLL).

Ofatumumab (Arzerra) is a fully human monoclonal antibody. Like rituximab, it is specific for the CD20 antigen found on B cells.

Ofatumumab was tested in a pivotal study in 154 patients with CLL, a type of B cell tumour. Among the 59 participants who were refractory to fludarabine and alemtuzumab, 58% responded to ofatumumab treatment. Response rates were comparable between those who had previously received rituximab and those who had not.

Arzerra has been conditionally approved by the European Medicines Agency; therefore, the agency will review any new data on the product annually.

View Arzerra drug record

Further information: GlaxoSmithKline

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more